drugset / Trial / NCT03302091

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

NCT03302091

Phase 1 Completed 20 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.

Timeline

Start
2017-10-17
Primary completion
2018-08-16
Completion
2018-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1467335 Unknown